We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its cancer treatment Opdualag for certain advanced melanoma patients.
The New York biopharmaceutical company said the recommendation covers the first-line treatment of unresectable or metastatic melanoma in patients 12 years of age and older with tumor cell PD-L1 expression < 1%.
The European Commission, which generally follows CHMP's advice, will now review the recommendation.
The U.S. Food and Drug Administration in March approved Opdualag, a combination of Bristol's blockbuster cancer drug Opdivo and its LAG-3-blocking antibody relatlimab, for patients 12 and older with unresectable or metastatic melanoma, the most serious type of skin cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 22, 2022 07:36 ET (11:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
